Bariatric surgery is associated with greater long-term heart risk reduction than weight-loss medications
This is an editorial summary of research originally reported by Medical Xpress – Health. ProductSafer does not claim ownership of the underlying research. All intellectual property belongs to the original publishers.
A Mayo Clinic study has found that both metabolic and bariatric surgery and GLP-1 medications improve cardiovascular health in people with obesity, but surgery was associated with significantly greater reductions in long-term cardiovascular risk. The study is a direct comparison of two leading obesity treatments, evaluating how each approach affects the overall risk of cardiovascular disease. The findings are published in Annals of Surgery.
# Editorial Summary
People struggling with obesity have two main medical options to improve their health: weight-loss surgery or medications like GLP-1 drugs (such as Ozempic and Wegovy). A new study from Mayo Clinic compared how well these approaches work and found that both can benefit heart health, but bariatric surgery appears to offer significantly greater protection against cardiovascular disease over the long term. This research, published in the Annals of Surgery, provides important evidence to help patients and doctors make informed treatment decisions.
The study directly evaluated metabolic and bariatric surgery, procedures that physically alter the digestive system to reduce food intake, against GLP-1 medications, which are increasingly popular as a non-surgical weight-loss option. While both treatments improved cardiovascular health markers in people with obesity, those who underwent surgery showed notably larger reductions in their overall risk of developing heart disease and related complications down the road. This suggests that for some patients, the more invasive surgical approach may offer better long-term heart protection.
It's important to note that surgery and medication each come with their own trade-offs. Bariatric surgery requires a major operation with recovery time and potential complications, while GLP-1 medications are less invasive but must be taken long-term and can be expensive. For consumers considering obesity treatment, the takeaway is to discuss both options thoroughly with your doctor. Your choice should weigh the cardiovascular benefits found in this research against your personal health status, lifestyle, risk tolerance, and whether you can access and afford either option. Individual factors matter, what's best for one person may not be best for another.
What you can do
- ✓If you're considering treatment for obesity, discuss with your doctor whether bariatric surgery might be appropriate for you, since this study shows it provides significantly greater long-term cardiovascular risk reduction compared to GLP-1 medications alone.
- ✓Ask your healthcare provider to explain the specific cardiovascular benefits and risks of bariatric surgery versus GLP-1 drugs like Ozempic and Wegovy so you can weigh the trade-offs between the non-surgical medication option and the more invasive surgical approach.
- ✓If you're currently taking GLP-1 medications for weight loss, use this research as a conversation starter with your doctor about whether you might benefit from exploring bariatric surgery as an alternative or complementary treatment for better long-term heart health protection.
Always consult a healthcare professional for personal medical advice.
Read the full report at the original source
Medical Xpress – HealthWas this finding useful?